A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

被引:5
|
作者
Metairie, Marie [1 ]
Benoit, Louise [1 ,2 ]
Koual, Meriem [1 ,2 ]
Bentivegna, Enrica [1 ]
Wohrer, Henri [1 ]
Bolze, Pierre-Adrien [3 ]
Kerbage, Yohan [4 ]
Raimond, Emilie [5 ]
Akladios, Cherif [6 ]
Carcopino, Xavier [7 ]
Canlorbe, Geoffroy [8 ,9 ,10 ]
Uzan, Jennifer [11 ]
Lavoue, Vincent [12 ]
Mimoun, Camille [13 ]
Huchon, Cyrille [13 ,16 ]
Koskas, Martin [14 ]
Costaz, Helene [15 ]
Margueritte, Francois [16 ]
Dabi, Yohann [17 ]
Touboul, Cyril [17 ]
Bendifallah, Sofiane [17 ]
Ouldamer, Lobna [15 ,18 ]
Delanoy, Nicolas [19 ]
Nguyen-Xuan, Huyen-Thu [1 ]
Bats, Anne-Sophie [1 ,20 ,21 ]
Azais, Henri [1 ,20 ,21 ]
机构
[1] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris AP HP, Dept Gynaecol Oncol & Breast Surg, F-75015 Paris, France
[2] Univ Paris Cite, Ctr Univ St Peres, INSERM UMR S 1124, F-75006 Paris, France
[3] Univ Lyon 1, Lyon Sud Univ Hosp, Dept Gynaecol & Oncol Surg & Obstet, Hosp Civils Lyon, F-69002 Lyon, France
[4] Univ Lille, Dept Gynaecol Surg, CHU Lille, F-59000 Lille, France
[5] Inst Alix Champagne Univ Hosp, Dept Obstet & Gynaecol, F-51100 Reims, France
[6] Hop Univ Strasbourg, Dept Gynaecol, F-67200 Strasbourg, France
[7] Aix Marseille Univ AMU, Univ Avignon, Hop Nord, Dept Obstet & Gynaecol, F-13397 Marseille, France
[8] Pitie Salpetriere, Assistance Publ Hop Paris AP HP, Dept Gynaecol & Breast Surg & Oncol, F-75013 Paris, France
[9] Sorbonne Univ, Ctr Rech St Antoine CRSA, Canc Biol & Therapeut, INSERM UMR S 938, F-75012 Paris, France
[10] Sorbonne Univ, Univ Inst Canc, F-75013 Paris, France
[11] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Obstet Gynecol & Reprod Med, F-94000 Creteil, France
[12] Univ Rennes 1, Hop Sud, Dept Gynaecol Surg, equipe 8, F-35000 Rennes, France
[13] Univ Paris, Hop Lariboisiere, Dept Gynaecol Oncol & Breast Surg, F-75010 Paris, France
[14] Hop Xavier Bichat, Assistance Publ Hop Paris AP HP, Div Gynaecol Oncol, F-75018 Paris, France
[15] Georges Francois Leclerc Ctr, Dept Surg Oncol, F-21000 Dijon, France
[16] Ctr Hosp Intercommunal Poissy St Germain en laye, Dept Gynaecol, Site Hosp Poissy, F-78498 Poissy, France
[17] Hop Tenon, AP HP Assistance Publ Hop Paris, Dept Gynaecol ans Obstet, F-75020 Paris, France
[18] Hop Univ Tours, Dept Gynaecol, F-37000 Tours, France
[19] Hop Europeen Georges Pompidou, AP HP Assistance Publ Hop Paris, Dept Med Oncol, F-75015 Paris, France
[20] Univ Paris Cite, Ctr Rech Cordeliers, INSERM UMR S 1147, F-75006 Paris, France
[21] Inst Canc Paris CARPEM, F-75006 Paris, France
关键词
epithelial ovarian cancer; FIGO stage IV; metastatic patterns; prognosis; pleural involvement; overall survival; FALLOPIAN-TUBE; CLASSIFICATION; SURVIVAL; DISEASE; IMPACT; RECOMMENDATIONS; CYTOREDUCTION; COMPLICATIONS; METASTASES; PATHOLOGY;
D O I
10.3390/cancers15030706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The identification of prognostic factors is important to improve the management of patients with ovarian cancer (OC). The staging classification of OC was revised in 2014 and 2018 by the FIGO (International Federation of Gynecology and Obstetrics) Gynecological Oncology Committee and dichotomizes stages IV into stage IVA and IVB. The FIGO classification aims to establish a disease severity scale and to group patients with similar prognoses. The objective of our retrospective, multicenter study was to assess the prognostic impact of this dichotomization and of the initial metastatic localization of patients with FIGO stage IV OC. We showed that, among our 307 patients, FIGO stage IVA patients had a worse prognosis than FIGO stage IVB patients. The initial pleural effusion was a factor of poor prognosis in terms of overall survival. We suggest a modification of the current FIGO staging classification. International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (p = 0.02) and 18 versus 25 months (p = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (p = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (p = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Correlation between plasma PSGL-1 and FIGO stage, tumor metastasis, and survival in epithelial ovarian cancer
    Li, WenHui
    Fang, Cheng
    Gao, Ya
    Gao, Yan
    Yan, FengShang
    Chen, BiLiang
    Xu, MingJuan
    BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2024, 71 (04) : 733 - 740
  • [22] Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
    Luo, Yanlin
    Lee, Maria
    Kim, Hee Seung
    Chung, Hyun Hoon
    Song, Yong Sang
    MEDICINE, 2016, 95 (36)
  • [23] Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors
    Shibata, K
    Kikkawa, F
    Mika, M
    Suzuki, Y
    Kajiyama, H
    Ino, K
    Mizutani, S
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (05) : 587 - 592
  • [24] Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes
    Ghirardi, Valentina
    Trozzi, Rita
    Scanu, Francesca Romana
    Giannarelli, Diana
    Santullo, Francesco
    Costantini, Barbara
    Naldini, Angelica
    Panico, Camilla
    Frassanito, Luciano
    Scambia, Giovanni
    Fagotti, Anna
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (05) : 3350 - 3360
  • [25] Diaphragmatic surgery during primary debulking in 89 patients with stage IIIB-IV epithelial ovarian cancer
    Tsolakidis, D.
    Amant, F.
    Van Gorp, T.
    Leunen, K.
    Neven, P.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 489 - 496
  • [26] Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers
    Sartorius, Celine Montavon
    Mirza, Uzma
    Schotzau, Andreas
    Mackay, Gillian
    Fink, Daniel
    Hacker, Neville F.
    Heinzelmann-Schwarz, Viola
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 4709 - 4718
  • [27] Patients with stage IV epithelial ovarian cancer: understanding the determinants of survival
    Dabi, Yohann
    Huchon, Cyrille
    Ouldamer, Lobna
    Bendifallah, Sofiane
    Collinet, Pierre
    Bricou, Alexandre
    Darai, Emile
    Ballester, Marcos
    Lavoue, Vincent
    Haddad, Bassam
    Touboul, Cyril
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [28] Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
    Chen, Jie-Ping
    Huang, Qi-Dan
    Wan, Ting
    Tu, Hua
    Gu, Hai-Feng
    Cao, Jun-Ya
    Liu, Ji-Hong
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [29] Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
    Jie-Ping Chen
    Qi-Dan Huang
    Ting Wan
    Hua Tu
    Hai-Feng Gu
    Jun-Ya Cao
    Ji-Hong Liu
    Journal of Ovarian Research, 12
  • [30] Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Trope, Claes G.
    Elstrand, Mari B.
    Sandstad, Berit
    Davidson, Ben
    Oksefjell, Halldis
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2146 - 2154